Bluebird, Celgene myeloma therapy improves with time, study finds

Minneapolis

A novel therapy from Bluebird Bio Inc and Celgene Corp for patients nearing death from an aggressive form of blood cancer appears to get more effective over time, wiping out signs of disease in more than half of those treated in a small trial.

A single infusion of the personalised therapy known as bb2121 generated a response in all but one of the 18 multiple myeloma patients treated at the highest dose, according to the study presented a…